140399-50-4

Upstream product

• 3949-36-8 3-acetylcoumarin 
• 100-52-7 benzaldehyde 
• 90-02-8 salicylaldehyde 
• 141-97-9 ethyl acetoacetate 
• 104-55-2 3-phenyl-propenal 
• 42996-88-3 methyl 3-oxo-5-phenyl-4-pentenoate 
• 140445-65-4 <2-(3-coumarinyl)-2-oxoethyl>triphenylphosphonium bromide 
• 140399-49-1 <2-(3-coumarinyl)-2-oxoethylidene>triphenylphosphorylide 

Downstream Products

• 76011-77-3 3-Phenyl-1-(2,2,4-triethyl-chroman-3-yl)-pentan-1-one 
• 76011-89-7 2-Oxo-4-(2-oxo-2H-chromen-3-yl)-6-phenyl-cyclohex-3-enecarboxylic acid ethyl ester 
• 76011-92-2 5-Oxo-5-(2-oxo-2H-chromen-3-yl)-2,3-diphenyl-pentanoic acid ethyl ester 
• 76011-70-6 3-(γ-phenyliminocinnamoyl)coumarin 
• 76011-72-8 3-[3-(2,4-Dimethyl-phenyl)-3-phenyl-propionyl]-chroman-2-one 
• 76011-71-7 3-[3-(4-Chloro-phenyl)-3-phenyl-propionyl]-chroman-2-one 
• 76011-86-4 3-(3-Oxo-4,5-diphenyl-cyclohex-1-enyl)-chromen-2-one 
• 76011-96-6 2-[3-Oxo-3-(2-oxo-2H-chromen-3-yl)-1-phenyl-propyl]-succinic acid dimethyl ester 
• 76011-85-3 3-(3-Oxo-2,4,5-triphenyl-cyclohex-1-enyl)-chromen-2-one 
• 929298-03-3 3-(4-phenyl-2,3-dihydro-1H-benzo[b][1,4]diazepin-2-yl)-chromen-2-one 
• 1032-97-9 3-(1H-benzimidazol-2-yl)coumarin 
• 716-79-0 2-phenyl-1H-benzoimidazole 
• 91527-74-1 3-(1,5-diphenyl-4,5-dihydro-1H-pyrazol-3-yl)-2H-chromen-2-one 
• 1240930-26-0 4-phenyl-2-(coumarin-3-yl)-6-(8-methoxycoumarin-3-yl)pyridine 

Relevant academic research and scientific papers

Studying the cytotoxicity of coumarin–chalcone hybrids by a prooxidant strategy in A549 cells

Abstract: Curcumin, bearing two electrophilic α,β-unsaturated ketones, is a promising anticancer agent by an electrophilicity-based prooxidant strategy (ROS-generating) due to the Michael acceptors. Considering that ROS generation depends on Michael acceptor unit, we have designed and synthesized two series coumarin–chalcone hybrids containing one or two Michael acceptor units through Claisen–Schmidt condensation, and evaluated the cytotoxicity against A549 cells as well as ROS accumulation. (E)-3-[3-(2-Hydroxyphenyl)acryloyl]-2H-chromen-2-one was identified as the strongest ROS inducer and cytotoxic agent. The structure–activity relationships (SAR) indicated that the Michael acceptor unit was more important than the position of hydroxyl to the cytotoxicity mediated by increasing the cellular lever of ROS. In addition, (E)-3-[3-(2-hydroxyphenyl)acryloyl]-2H-chromen-2-one caused S-phase cell cycle arrest in A549 cells. Therefore, this work provides an example of coumarin–chalcone scaffold as cytotoxic agent by a prooxidant (ROS-generating agent) strategy. Graphical abstract: [Figure not available: see fulltext.].

Thiazolyl-pyrazole-biscoumarin synthesis and evaluation of their antibacterial and antioxidant activities

Abstract: A series of novel 3-(2-oxo-2H-chromen-3-yl)-1-(4-(2-oxo-2H-chromen-3-yl)thiazol-2-yl)-5-aryl-1H-pyrazol-1-ium bromides have been prepared through a one-pot three-component cyclocondensation of various coumarin chalcones, thiosemicarbazide and 2-

USE OF SYNTHESIZED COMPOUNDS AS AN INHIBITOR OF EF2-KINASE ENZYME

The invention is related to the use of synthesized compounds, as an inhibitor of the EF2-Kinase enzyme which is active in breast, pancreas, brain, ovarian, lung, skin (melanoma) and blood cancers. The aim of this invention is to make use of synthesized co

Novel coumarin-pyrazoline hybrids: synthesis, cytotoxicity evaluation and molecular dynamics study

A novel series of coumarin-pyrazoline hybrids3a-f,4a-cand5a-chave been synthesized and tested for their antiproliferative activity against the breast cancer cell line MCF-7. The most active compounds3d,3e,3f,5aand5cwere also evaluated for their ability to

Synthesis and biological evaluation of new coumarin derivatives as cytotoxic agents

New coumarin derivatives 9a–f, 10a–e, and 11a–f were synthesized and evaluated for their cytotoxic activity against a human breast cancer cell line (MCF-7). All compounds exhibited good activity in the nanomolar range, using doxorubicin and erlotinib as positive controls. The most active compound 9d with IC50 of 21 nM was tested against the HCT-116, HepG-2, A549, and SGC-7901 cell lines, with IC50 values of 0.021, 0.170, 0.028, and 0.11 μM, respectively. Compound 9d was further investigated for its ability to suppress the expression of epidermal growth factor receptor (EGFR). Compound 9d decreased the concentration of EGFR by 87%, using erlotinib as a positive control. A docking study revealed similar or higher scores than for erlotinib and similar binding poses providing interactions with the hinge region of the tyrosine kinase (TK). Besides the effect on expression, this in silico investigation predicts the possibility of direct binding between the new coumarin derivatives and the EGFR TK. Moreover, computational calculation for ADME properties for the most active compounds 9d, 9e, 10c, and 11c revealed the expected high gastrointestinal tract absorption, moderate water solubility with no central nervous system toxicity, and druglikeness.

EF2-KINASE ENZYME INHIBITING NOVEL COMPOUNDS

The invention is related to synthesis of novel compounds that inhibit the EF2-Kinase enzyme which is effective in breast, pancreas, brain, ovary, lung, skin (melanoma) and blood cancers.

Rationally synthesized coumarin based pyrazolines ameliorate carrageenan induced inflammation through COX-2/pro-inflammatory cytokine inhibition

In the present work, coumarin based pyrazolines (7a-g) have been synthesized and investigated for their in vitro and in vivo anti-inflammatory potential. Amongst the synthesized compounds, compounds 7a, 7d and 7f exhibited significant in vitro anti-inflammatory activity as compared to the standard etoricoxib. Keeping this in mind, in vivo investigations were carried out via carrageenan induced inflammation and acetic acid induced writhing models in male Wistar rats and compound 7a was found to possess appreciable anti-inflammatory and analgesic potential. The mode of action of compound 7a was also investigated by using substance P as the biomarker, which shows promising results. Further, the selectivity of the most active compound 7a against the cyclooxygenase enzyme was supported by molecular docking studies which reveal that compound 7a has greater binding affinity towards COX-2 over COX-1 and 5-LOX enzymes. In silico ADME analysis of compound 7a confirms the drug-like characteristics and the in vivo acute toxicity study showed the safety of the compound even up to a 2000 mg kg?1 dose. Thus, compound 7a was identified as an effective anti-inflammatory agent, and can be explored for further analgesic/anti-inflammatory drug design and development.

ZnS nanoparticles immobilized on graphitic carbon nitride as a recyclable and environmentally friendly catalyst for synthesis of 3-cinnamoyl coumarins

Abstract: Zinc oxide nanoparticles immobilized on a graphitic carbon nitride (ZnS NPs/g-C3N4) nanocomposite were applied as an organometallic recyclable catalyst in the synthesis of coumarin–chalcone hybrids through the Claisen–Schmi

Method for synthesizing coumarin-based chalcone type compound by one-pot process

The invention provides a method for synthesizing a coumarin-based chalcone type compound by a one-pot process and belongs to the technical field of organic synthesis. The method comprises the following synthetic processes as shown in the description: addi

Cross-aldol reaction of 3-acetyl-2H-chromen-2-one by using Amberlyst 26A as catalyst

Synthesis of a series of 3-acetylcoumarin-derived chalcones (1a–16a) was catalyzed with Amberlyst 26A in ethanol. Using reusable Amberlyst 26A and biobased solvent ethanol make this method highly ecofriendly and simple. Amberlyst 26A was found to be a highly effective catalyst for cross aldol reaction. The results shown that the method is operationally simple to implement with a wide scope of substrates.